Inogen (INGN) Upgraded to Hold by BidaskClub

Inogen (INGN) Upgraded to Hold by BidaskClub

BidaskClub upgraded shares of Inogen (NASDAQ:INGN) from a sell rating to a hold rating in a report published on Friday, October 19th.

A number of other equities analysts also recently weighed in on the stock. Zacks Investment Research raised shares of Inogen from a hold rating to a buy rating and set a $290.00 target price for the company in a research note on Thursday, September 27th. Piper Jaffray Companies boosted their target price on shares of Inogen from $245.00 to $290.00 and gave the stock an overweight rating in a research note on Wednesday, September 12th. Needham & Company LLC downgraded shares of Inogen from a strong-buy rating to a buy rating and boosted their target price for the stock from $254.00 to $296.00 in a research note on Monday, September 10th. Finally, Stifel Nicolaus set a $258.00 target price on shares of Inogen and gave the stock a buy rating in a research note on Tuesday, August 21st. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $244.67.

NASDAQ:INGN traded down $1.96 on Friday, reaching $137.97. The stock had a trading volume of 688,800 shares, compared to its average volume of 257,768. Inogen has a 1-year low of $112.78 and a 1-year high of $287.79. The firm has a market cap of $3.17 billion, a PE ratio of 105.32, a price-to-earnings-growth ratio of 2.89 and a beta of 1.56.

Inogen (NASDAQ:INGN) last announced its earnings results on Tuesday, November 6th. The medical technology company reported $0.73 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.52 by $0.21. Inogen had a net margin of 12.28% and a return on equity of 18.91%. The company had revenue of $95.29 million during the quarter, compared to the consensus estimate of $90.94 million. During the same period in the previous year, the firm posted $0.33 earnings per share. The company’s revenue was up 38.0% on a year-over-year basis. Analysts expect that Inogen will post 2.1 earnings per share for the current fiscal year.

In related news, Director Raymond Huggenberger sold 10,500 shares of the business’s stock in a transaction that occurred on Wednesday, August 15th. The shares were sold at an average price of $228.63, for a total transaction of $2,400,615.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Brenton Taylor sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $259.42, for a total transaction of $1,297,100.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 48,000 shares of company stock valued at $11,409,090. 5.29% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently bought and sold shares of INGN. Zacks Investment Management increased its stake in Inogen by 1.6% in the second quarter. Zacks Investment Management now owns 17,033 shares of the medical technology company’s stock valued at $3,174,000 after purchasing an additional 261 shares in the last quarter. Fuller & Thaler Asset Management Inc. increased its stake in Inogen by 0.4% in the second quarter. Fuller & Thaler Asset Management Inc. now owns 72,381 shares of the medical technology company’s stock valued at $13,487,000 after purchasing an additional 291 shares in the last quarter. Sei Investments Co. increased its stake in Inogen by 10.5% in the first quarter. Sei Investments Co. now owns 3,073 shares of the medical technology company’s stock valued at $377,000 after purchasing an additional 293 shares in the last quarter. Xact Kapitalforvaltning AB increased its stake in Inogen by 12.2% in the second quarter. Xact Kapitalforvaltning AB now owns 2,765 shares of the medical technology company’s stock valued at $515,000 after purchasing an additional 300 shares in the last quarter. Finally, Advisory Services Network LLC increased its stake in Inogen by 162.5% in the third quarter. Advisory Services Network LLC now owns 525 shares of the medical technology company’s stock valued at $128,000 after purchasing an additional 325 shares in the last quarter. 96.00% of the stock is owned by institutional investors and hedge funds.

About Inogen

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

See Also: What are the economic characteristics of a bear market?

Related posts

Leave a Comment

Inogen (INGN) Boosted to Hold by BidaskClub

BidaskClub upgraded shares of Inogen (NASDAQ:INGN) from a sell rating to a hold rating in a report published on Friday, October 19th.

Inogen Inc logo

A number of other equities analysts also recently weighed in on the stock. Zacks Investment Research raised shares of Inogen from a hold rating to a buy rating and set a $290.00 target price for the company in a research note on Thursday, September 27th. Piper Jaffray Companies boosted their target price on shares of Inogen from $245.00 to $290.00 and gave the stock an overweight rating in a research note on Wednesday, September 12th. Needham & Company LLC downgraded shares of Inogen from a strong-buy rating to a buy rating and boosted their target price for the stock from $254.00 to $296.00 in a research note on Monday, September 10th. Finally, Stifel Nicolaus set a $258.00 target price on shares of Inogen and gave the stock a buy rating in a research note on Tuesday, August 21st. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $244.67.

NASDAQ:INGN traded down $1.96 on Friday, reaching $137.97. The stock had a trading volume of 688,800 shares, compared to its average volume of 257,768. Inogen has a 1-year low of $112.78 and a 1-year high of $287.79. The firm has a market cap of $3.17 billion, a PE ratio of 105.32, a price-to-earnings-growth ratio of 2.89 and a beta of 1.56.

Inogen (NASDAQ:INGN) last announced its earnings results on Tuesday, November 6th. The medical technology company reported $0.73 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.52 by $0.21. Inogen had a net margin of 12.28% and a return on equity of 18.91%. The company had revenue of $95.29 million during the quarter, compared to the consensus estimate of $90.94 million. During the same period in the previous year, the firm posted $0.33 earnings per share. The company’s revenue was up 38.0% on a year-over-year basis. Analysts expect that Inogen will post 2.1 earnings per share for the current fiscal year.

In related news, Director Raymond Huggenberger sold 10,500 shares of the business’s stock in a transaction that occurred on Wednesday, August 15th. The shares were sold at an average price of $228.63, for a total transaction of $2,400,615.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Brenton Taylor sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $259.42, for a total transaction of $1,297,100.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 48,000 shares of company stock valued at $11,409,090. 5.29% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently bought and sold shares of INGN. Zacks Investment Management increased its stake in Inogen by 1.6% in the second quarter. Zacks Investment Management now owns 17,033 shares of the medical technology company’s stock valued at $3,174,000 after purchasing an additional 261 shares in the last quarter. Fuller & Thaler Asset Management Inc. increased its stake in Inogen by 0.4% in the second quarter. Fuller & Thaler Asset Management Inc. now owns 72,381 shares of the medical technology company’s stock valued at $13,487,000 after purchasing an additional 291 shares in the last quarter. Sei Investments Co. increased its stake in Inogen by 10.5% in the first quarter. Sei Investments Co. now owns 3,073 shares of the medical technology company’s stock valued at $377,000 after purchasing an additional 293 shares in the last quarter. Xact Kapitalforvaltning AB increased its stake in Inogen by 12.2% in the second quarter. Xact Kapitalforvaltning AB now owns 2,765 shares of the medical technology company’s stock valued at $515,000 after purchasing an additional 300 shares in the last quarter. Finally, Advisory Services Network LLC increased its stake in Inogen by 162.5% in the third quarter. Advisory Services Network LLC now owns 525 shares of the medical technology company’s stock valued at $128,000 after purchasing an additional 325 shares in the last quarter. 96.00% of the stock is owned by institutional investors and hedge funds.

About Inogen

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

See Also: What are the economic characteristics of a bear market?

Analyst Recommendations for Inogen (NASDAQ:INGN)

Related posts

Leave a Comment